Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.2961
22.8166
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
EUZ
stock under the Base Case scenario is
20.6
EUR.
Compared to the current market price of 15.47 EUR,
Eckert & Ziegler Strahlen und Medizintechnik AG
is
Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Eckert & Ziegler Strahlen und Medizintechnik AG.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Eckert & Ziegler Strahlen und Medizintechnik AG
Balance Sheet Decomposition
Eckert & Ziegler Strahlen und Medizintechnik AG
| Current Assets | 244.6m |
| Cash & Short-Term Investments | 121m |
| Receivables | 70.4m |
| Other Current Assets | 53.1m |
| Non-Current Assets | 207.5m |
| Long-Term Investments | 15.5m |
| PP&E | 130.8m |
| Intangibles | 45.5m |
| Other Non-Current Assets | 15.7m |
| Current Liabilities | 83.5m |
| Accounts Payable | 8m |
| Other Current Liabilities | 75.5m |
| Non-Current Liabilities | 137m |
| Long-Term Debt | 37m |
| Other Non-Current Liabilities | 100m |
Free Cash Flow Analysis
Eckert & Ziegler Strahlen und Medizintechnik AG
| EUR | |
| Free Cash Flow | EUR |
Earnings Waterfall
Eckert & Ziegler Strahlen und Medizintechnik AG
|
Revenue
|
304.5m
EUR
|
|
Cost of Revenue
|
-160.6m
EUR
|
|
Gross Profit
|
143.9m
EUR
|
|
Operating Expenses
|
-79.1m
EUR
|
|
Operating Income
|
64.8m
EUR
|
|
Other Expenses
|
-25m
EUR
|
|
Net Income
|
39.8m
EUR
|
EUZ Profitability Score
Profitability Due Diligence
Eckert & Ziegler Strahlen und Medizintechnik AG's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Eckert & Ziegler Strahlen und Medizintechnik AG's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
EUZ Solvency Score
Solvency Due Diligence
Eckert & Ziegler Strahlen und Medizintechnik AG's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Score
Eckert & Ziegler Strahlen und Medizintechnik AG's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EUZ Price Targets Summary
Eckert & Ziegler Strahlen und Medizintechnik AG
According to Wall Street analysts, the average 1-year price target for
EUZ
is 22.92 EUR
with a low forecast of 21.92 EUR and a high forecast of 25.2 EUR.
Dividends
Current shareholder yield for
EUZ is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
EUZ
stock under the Base Case scenario is
20.6
EUR.
Compared to the current market price of 15.47 EUR,
Eckert & Ziegler Strahlen und Medizintechnik AG
is
Undervalued by 25%.